Category: Active Surveillance

Who is the world’s leading prostate cancer expert? How does one even begin to answer that question? There are so many great minds dealing with prostate cancer from so many angles: biology, urology, radiology, oncology, pathology and more—it’s impossible to identify a single authority on the subject. However, when great minds work together, powerful consensus keep reading

In recent years, there’s been a huge groundswell of Active Surveillance (AS) for low-risk prostate cancer (PCa) patients. In fact, it’s considered the preferred PCa management strategy for men with lower-risk disease. There are two primary factors at play: 1) patient resistance to undergoing definitive whole gland treatments that can impair urinary and sexual function, keep reading

“Despite increasing adoption of active surveillance (AS) for low-risk prostate cancer, AS discontinuation rates are high, investigators report.” This quote, from a September 2021 Renal & Urology News report, referred to a study of over 16,000 Canadian prostate cancer (PCa) patients who had been diagnosed with low risk disease from 2008-2014. 51% of these patients keep reading

In recent years, there’s been a huge shift in understanding the difference between insignificant and significant prostate cancer (PCa). Over 15 years ago, Albertsen, et al. (2005) established that clinically insignificant PCa could be defined as cancer that “will not affect the patient during the natural course of his lifetime. The indolent course of localised keep reading

Fourteen months prior to the time of this writing, the world began locking down due to the emerging SARS-CoV-2 viral pandemic and the potentially deadly COVID illness it causes. We were all confused, and studies repeatedly show that normal screening for cancers such as breast, prostate and colorectal dropped significantly... keep reading

Good news! The widespread integration of multiparametric MRI (mpMRI) and MRI-guided targeted biopsies has resulted in both better initial qualification of AS candidates, and significantly better ability to monitor for significant PCa by PSA + mpMRI. As a side benefit... keep reading

The rate of newly diagnosed patients with Gleason 3+3 (Grade Group 1) prostate cancer who choose go on Active Surveillance instead of immediate treatment has increased significantly in the last decade. There’s considerable expert opinion that... keep reading

“Slow and steady wins the race.” – From “The Hare and the Tortoise” by Aesop We often long for quick results, especially when it comes to health. Countless ads for supplements and exercise aids that promise “Fast Results!” draw hordes of consumers. Sadly, many buyers have found, to their great disappointment, that immediate gratification is keep reading

If you wanted to know what men look for in choosing a new car, it seems obvious that function would be a top priority. They want reliable transportation. After that, what matters will vary from one man to another. Budget, of course, will be a consideration. Next, choices depend on things like repair record, safety, keep reading

Question: What goes up and hasn’t come down? Answer: The use of Active Surveillance in the U.S. A February, 2019 study[i] examined U.S. management trends for low-risk prostate cancer since 2010. Prior to that, the standard of care for low-to-intermediate risk PCa was an “elephant gun” approach aimed at eradicating PCa by obliterating the gland. keep reading